Recursion Pharmaceuticals (NASDAQ:RXRX) is set to give its latest quarterly earnings report on Wednesday, 2026-02-25. Here's what investors need to know before the announcement.

Analysts estimate that Recursion Pharmaceuticals will report an earnings per share (EPS) of $-0.30.

Investors in Recursion Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Past Earnings Performance

Last quarter the company beat EPS by $0.02, which was followed by a 6.85% drop in the share price the next day.

Here's a look at Recursion Pharmaceuticals's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.38	-0.35	-0.52	-0.42
EPS Actual	-0.36	-0.41	-0.50	-0.53
Price Change %	-7.00	-1.00	-13.00	-2.00

Tracking Recursion Pharmaceuticals's Stock Performance

Shares of Recursion Pharmaceuticals were trading at $3.41 as of February 23. Over the last 52-week period, shares are down 57.73%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

Analyst Opinions on Recursion Pharmaceuticals

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Recursion Pharmaceuticals.

With analyst ratings, Recursion Pharmaceuticals has a consensus rating of . The average one-year price target is $, indicating a potential .

To track all earnings releases for Recursion Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.